Comparing a new medication to standard treatment before breast cancer surgery
Part of Cancer, Skin clinical trials.
This trial tests a new medication (HLX319) against an approved treatment (Phesgo) given before surgery for HER2-positive breast cancer. The goal is to see if the new drug works just as well and is safe, potentially offering another option to help shrink tumors before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have HER2-positive breast cancer (a specific protein marker) that is stage II to IIIC (meaning it has not spread to distant organs).
- You must agree to have surgery after the initial treatment period.
- Your heart function must be good (at least 55% ejection fraction).
- You must be in generally good health (able to carry out everyday activities) and have adequate organ function.
- You must not have had prior cancer treatment (like chemo or radiation) for this breast cancer, and you must not have other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of targeted drugs (HLX87 with HLX22 or pertuzumab) given before breast cancer surgery. The goal is to shrink the tumor and improve treatment outcomes for people with HER2-positive breast cancer.
This trial tests two study drugs, HLX22 and HLX87, together for people with HER2-positive breast cancer that has spread or come back. It may be an option if you haven't yet had chemotherapy or HER2-targeted therapy for advanced disease.
This trial tests a new drug called HLX22 combined with standard treatments (trastuzumab and chemotherapy) for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. The goal is to see if this combination helps shrink tumors or slow the cancer's growth.
This trial tests a new version of a medication used for breast cancer. Because healthy people are needed first, it checks how the body processes the new drug and whether it causes side effects, helping to ensure it is safe before patients use it.
This trial tests a new drug (HLX43) for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests a new drug, QL1706, given alongside chemotherapy before surgery for a certain type of breast cancer. It aims to see if this combination helps shrink tumors before they are removed.
Hear when a new HER2 + Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.